Patents by Inventor Eddy W. Yue

Eddy W. Yue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130059835
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 31, 2012
    Publication date: March 7, 2013
    Applicant: INCYTE CORPORATION
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty
  • Patent number: 8372870
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: February 12, 2013
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Publication number: 20120157430
    Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: December 19, 2011
    Publication date: June 21, 2012
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, JR., Richard B. Sparks
  • Publication number: 20120058079
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: November 11, 2011
    Publication date: March 8, 2012
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • Patent number: 8088803
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: January 3, 2012
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • Publication number: 20110311479
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Application
    Filed: August 29, 2011
    Publication date: December 22, 2011
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Publication number: 20110281884
    Abstract: The present invention provides fused derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 17, 2011
    Inventors: Andrew P. Combs, Richard B. Sparks, Eddy W. Yue
  • Patent number: 8034953
    Abstract: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: October 11, 2011
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue
  • Publication number: 20110190319
    Abstract: The present invention provides fused derivatives of Formula I: that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: December 17, 2010
    Publication date: August 4, 2011
    Inventors: Andrew P. Combs, Yun-Long Li, Eddy W. Yue, Richard B. Sparks
  • Publication number: 20110183985
    Abstract: The present invention provides fused aryl and heteroaryl derivatives of Formula I: wherein X, V, Y, U, W, Z, R1, R2, Cy, and Ar are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: December 17, 2010
    Publication date: July 28, 2011
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Hui-Yin Li
  • Publication number: 20100015178
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: July 7, 2009
    Publication date: January 21, 2010
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • Publication number: 20090286778
    Abstract: The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    Type: Application
    Filed: April 23, 2009
    Publication date: November 19, 2009
    Applicant: INCYTE CORPORATION
    Inventors: Andrew Paul Combs, Richard B. Sparks, Eddy W. Yue, Hao Feng, Michael Jason Bower, Wenyu Zhu
  • Patent number: 6844318
    Abstract: This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.
    Type: Grant
    Filed: March 15, 2001
    Date of Patent: January 18, 2005
    Assignee: Bristol Myers Squibb Pharma Company
    Inventors: Robert A. Copeland, Charles F. Albright, Andrew P. Combs, Randine L. Dowling, Nilsa R. Graciani, Wei Han, C. Anne Higley, Pearl S. Huang, Eddy W. Yue, Susan V. DiMeo
  • Patent number: 6706718
    Abstract: The present invention relates to 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones of formula I: which are potent inhibitors of cyclin dependent kinases. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: March 16, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventor: Eddy W. Yue
  • Publication number: 20020107274
    Abstract: The present invention relates to 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-ones of formula 1
    Type: Application
    Filed: November 30, 2001
    Publication date: August 8, 2002
    Inventor: Eddy W. Yue
  • Publication number: 20020103133
    Abstract: This invention is directed to antineoplastic agents conjugated to enzyme-cleavable peptides comprising the amino acid recognition sequence of a membrane-bound and/or cell-secreted peptidase, and to the use of such conjugated compounds as chemotherapeutic agents in the targeted treatment of cancers.
    Type: Application
    Filed: March 15, 2001
    Publication date: August 1, 2002
    Inventors: Robert A. Copeland, Charles F. Albright, Andrew P. Combs, Randine L. Dowling, Nilsa R. Graciani, Wei Han, C. A. Higley, Pearl S. Huang, Eddy W. Yue, Susan V. DiMeo
  • Patent number: 6413957
    Abstract: The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
    Type: Grant
    Filed: August 15, 2000
    Date of Patent: July 2, 2002
    Assignee: Bristol-Myers Suibb Pharma Company
    Inventors: David A. Nugiel, David J. Carini, Susan V. Di Meo, Eddy W. Yue
  • Patent number: 6407103
    Abstract: The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: June 18, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: David A. Nugiel, David J. Carini, Susan V. Di Meo, Eddy W. Yue
  • Publication number: 20010027195
    Abstract: The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1
    Type: Application
    Filed: December 6, 2000
    Publication date: October 4, 2001
    Inventors: David A. Nugiel, David J. Carini, Susan V. DiMeo, Eddy W. Yue
  • Patent number: 6291504
    Abstract: The present invention relates to the synthesis of a new lass of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: September 18, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: David A. Nugiel, David J. Carini, Susan V. Di Meo, Anup P. Vidwans, Eddy W. Yue